Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440324 | 1.00 | KDM4E (0.48) | KDM4ETSHRPIN1MEN1KMT2A | |
| SCHEMBL29932506 | 1.00 | KDM4E (0.48) | KDM4ETSHRPIN1MEN1KMT2A | |
| SCHEMBL25598182 | 0.89 | KDM4E (0.43) | KDM4ETSHRPIN1MEN1KMT2A | |
| SCHEMBL31109931 | 0.89 | KDM4E (0.43) | KDM4ETSHRPIN1ARGAA | |
| SCHEMBL24980794 | 0.88 | KDM4E (0.41) | KDM4ETSHRPIN1ARGAA | |
| SCHEMBL29946658 | 0.88 | KDM4E (0.41) | KDM4ETSHRPIN1ARGAA | |
| SCHEMBL30591262 | 0.86 | KDM4E (0.40) | KDM4ETSHRPIN1ARGAA | |
| SCHEMBL25598741 | 0.86 | KDM4E (0.40) | KDM4ETSHRPIN1ARGAA | |
| SCHEMBL24981617 | 0.85 | KDM4E (0.39) | KDM4ETSHRPIN1ARGAA | |
| SCHEMBL30591273 | 0.85 | PIN1 (0.40) | KDM4ETSHRPIN1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055156-A | (R) -N-ethyl-5-fluoro-N-isopropyl-2- ((5- (2- (6- ((2-methoxyethyl) (methyl) amino) -2-methyl-hex-3-yl) -2, 6-diazaspiro [3.4] oct-6-yl) -1,2, 4-triazin-6-yl) oxy) benzamide, formulations and dosing regimens for treating cancer | 詹森药业有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260125387-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-07 | — | — | US | disclosed |
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| EP-4698182-A1 | COMBINATION OF A MENIN-LL1 INHIBITOR, A DNA INTERCALATING AGENT AND A PYRIMIDINE ANALOGUE TO TREAT A HEMATOPOIETIC DISORDER | Janssen Pharmaceutica NV (BE) | 2026-02-25 | — | — | EP | disclosed |
| US-12473295-B2 | Substituted straight chain spiro derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-18 | — | — | US | disclosed |
| US-20250302840-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2025-10-02 | — | — | US | disclosed |
| EP-4581032-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025082444-A2 | (R) -N-ETHYL-5-FLUORO-N-ISOPROPYL-2- ( (5- (2- (6- ( (2-METHOXYETHYL) (METHYL) AMINO) -2-METHYLHEXAN-3-YL) -2, 6-DIAZASPIRO [3.4] OCTAN-6-YL) -1, 2, 4-TRIAZIN-6-YL) OXY) BENZAMIDE, FORMULATIONS AND DOSAGE REGIMENS THEREOF, FOR USE IN TREATING CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-24 | — | — | WO | disclosed |
| CN-118845787-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118852178-A | Compounds for the treatment of diseases such as cancer | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230142285-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| WO-2022262796-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-M ETHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT FOR THE TREATMENT OF DISEASES SUCH AS CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022262796-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-M ETHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT FOR THE TREATMENT OF DISEASES SUCH AS CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237720-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| EP-4077312-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | Janssen Pharmaceutica NV (BE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114867721-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021121327-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021121327-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302840-A1 | COMBINATION THERAPIES | MEN1, MLLT1, BMI1 | KDM4E 395/4885TSHR 4565/4885PIN1 4459/4885 |
| US-12473295-B2 | Substituted straight chain spiro derivatives | MLLT1, MEN1, MLLT3 | KDM4E 911/4885TSHR 3952/4885PIN1 2103/4885 |
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | CBR1, CNR1, CBR3 | KDM4E 3502/4885TSHR 98/4885PIN1 1665/4885 |
| US-20230142285-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | MLLT1, MEN1, MLLT3 | KDM4E 911/4885TSHR 3952/4885PIN1 2103/4885 |
| US-20260125387-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | MLLT1, MEN1, MLLT3 | KDM4E 141/4885TSHR 2644/4885PIN1 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.